Safety of a High Bolus Dose of Tirofiban in Patients Undergoing Coronary Stent Placement

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 2, 2004, Pages 179-184

  Danzi, Gian B ^a,b   Capuano, Cinzia ^a   Sesana, Marco ^a   Baglini, Roberto ^a  

^a Poliambulanza Hospital   (Italy)

^b Catheterization Laboratory   (Italy)

Author keywords

Abciximab; Coronary disease; Stenting; Tirofiban

Indexed keywords

ABCIXIMAB; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BOLUS INJECTION; CORONARY ARTERY DISEASE; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME; TYROSINE;

EID: 0742270475     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10734     Document Type: Article

References (22)

1. Topol EJ, Byzova TV, Plow EF. Platelet GP IIb-IIIa blockers. Lancet 1999;353:227-231.
2. Cook JJ, Bednar B, Lynch JJ, Gould RJ, Egbertson MS, Halczenko W, Duggan ME, Hartmann GD, Lo MW, Murphy GM. Tirofiban (Aggrastat). Cardiovasc Drug Rev 1999;17:199-224.
3. RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
4. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L. Comparison of two glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
5. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implication for coronary interventions. Am J Cardiol 2002;89:647-650.
6. Herrmann HC, Swerkosz TA, Kapoor S, Tardiff DC, DiBattiste PM, Hirshfeld JW, Klugherz BD, Kolansky DM, Magness K, Valettas N, Wilensky RL. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2002;89:1293-1297.
7. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, Kabbani SS, DiBattiste PM. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421-1423.
8. Tommasini G, Rubartelli P, Piaggio M. A deterministic approach to automated stenosis quantification. Catheter Cardiovasc Interv 1999;48:435-445.
9. Danzi GB, Pirelli S, Mauri L, Testa R, Ciliberto GR, Massa D, Lotto AA, Campolo L, Parodi O. Which variable of stenosis severity best describes the significance of an isolated left anterior descending coronary artery lesion? correlation between quantitative coronary angiography, intracoronary Doppler measurements and high dose dipyridamole echocardiography. J Am Coll Cardiol 1998;31:526-533.
10. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation 1988;78:486-502.
11. Cannon CP, Weintraub WS, Dempoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndrome treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
12. Jurgens CP, White HD, Belardi JA, Macaya C, Soler-Soler J, Meyer BJ, Levy RD, Bunt T, Menten J, Herrman HC, Adgey AA, Tarnesby G. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clin Ther 2002;24:1332-1344.
13. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, Aggarwal A, Kabbani SS, DiBattiste PM. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus dose of tirofiban. Am J Cardiol 2003;91:334-336.
14. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-554.
15. Mazur W, Kaluza G, Sapp S, et al. Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the valuation of platelet IIb/IIIa inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. Am Heart J 2002;143:594-601.
16. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-1536.
17. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-466.
18. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002;40:1961-1967.
19. Stone GW, Mehran R, Dangas G, Lansky AJ, Komowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104:642-647.
20. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIB/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-444.
21. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997;336:1689-1696.
22. Braunwald E, Antman EM, Beasley JW, et al. Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article-a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2002;40:1366-1374.